Sanwa Chemical Strengthens Overseas Contract Pharmaceutical Production Business
This article was originally published in PharmAsia News
Nagoya-based Sanwa Kagaku will expand its overseas contract manufacturing business, including technology to manufacture three-layered tablets in which the thickness of each layer can be changed easily. Aiming to increase its contract production business to 20 percent of total sales, the company completed a research facility in Japan's Mie Prefecture in January. (Click here for more - Japanese language
You may also be interested in...
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Janet Woodcock’s 2019 prediction that record ANDA approval volumes would not continue is confirmed with the FY 2020 approval total down 21% from the previous year.
Deal snapshot: Resolving a loose end from its 2014 buyout of Auxilium, Endo acquires all rights to Xiaflex, along with approved cellulite therapy Qwo.